News for Zymeworks Inc (0OX.BE)

Zymeworks Inc. (ZYME) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Construction of a 40,000-square-foot bio-manufacturing centre in Metro Vancouver has always been the cornerstone to James Taylor’s strategic vision for the company he co-founded.

Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) ...

during the forecast period. Growth in this market is primarily attributed to increasing funds and grants by government bodies and universities for the development of novel biomaterials, increasing demand for implantable devices, growing demand for biomaterials in plastic surgery and wound healing applications, rising incidences of cardiovascular diseases, and rising awareness and research on regenerative medicine.New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomaterials Market by Type of Materials, Application - Global Forecast to 2025" - https://www.reportlinker.com/p04604339/?utm_source=GNW By metallic biomaterials segment, the Titanium & Titanium Alloys segment accounted for the fastest-growing segment of thebiomaterials market.On the basis of type, the metallic biomaterials are further segmented as Stainless Steel, Titanium & Titanium Alloys, Cobalt-Chrome Alloys, Gold, Silver, and Magnesium. TheTitanium & Titanium Alloys accounted for the fastest-growing segment of the metallic biomaterials segment. sThese biomaterials do not show any form of toxicity or allergic reactions on contact with the body. Additionally, factors such as excellent biocompatibility, corrosion resistance, the balance of mechanical properties, and low weight stimulate the demand for titanium-based biomaterials.By Cardiovascular application segment, stents Catheters accounted for the largest share of the biomaterials marketBased on application, the cardiovascular application market is categorized into nine sub-segments— Catheters, Stents, Implantable Cardiac Defibrillators, Pacemakers, Sensors, Heart Valves, Vascular Grafts, Guidewires, and Other products.Catheters accounted for the largest share of the cardiovascular application segment due to the shift in patient preference from traditional open surgeries to minimally invasive surgeries.This trend is expected to propel the use of catheters and in turn, drive the growth of the biomaterials market during the forecast period.Asia Pacific: The fastest-growing region in the biomaterials market.The Asia Pacific region is estimated to grow at the highest CAGR in the biomaterials market during the forecast period, this is mainly due to Japan’s growing healthcare industry, increasing geriatric population, rising number of cosmetic and plastic surgeries in India, lucrative medical devices industry, and favorable tax policies in China.North America: the largest share of the biomaterials marketNorth America accounted for the largest share of the biomaterials market.Factors such as rising biomaterials-based research, growing demand for plastic surgeries, increase in cancer incidence, and the growing number of cardiovascular diseases are contributing to the growth of the biomaterials market in the US.In Canada, market growth is mainly driven by increasing funding for biomaterials and increasing R&D activity.Breakdown of primariesThe study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:• By Company– Tier 1 - 37%, Tier 2- 22%, Tier 3- 41%• By Designation— C Level - 25%, Directors - 20%, Others - 55%• By Region— North America - 40%, Europe - 27%, APAC – 20%, RoW- 13%The biomaterials market is dominated by a few globally established players such as BASF SE (Germany), Covestro AG (Germany), Celanese Corporation (Germany),Carpenter Technology (US), Corbion (Netherlands), Royal DSM (Netherlands), Evonik Industries (Germany), Mitsubishi Chemical Holdings Corporation (Japan), Victrex Plc (UK), Berkeley Advanced Biomaterials (US), GELITA AG (Germany), Zeus Industrial Products, Inc. (US), Cam Bioceramics (Netherlands), Solvay (US), AB Specialty Silicones (US), CoorsTek (US), CeramTec GmbH (Germany), The Lubrizol Corporation (US), Olympus Terumo Biomaterials Corporation (Japan), Xylos Corporation (US), Noble Biomaterials, Inc. (US), Dimension Inx (US), Artoss, Inc. (US), RDI Group (US), and Riton Biomaterial Co., Ltd. (China).Research Coverage:The report segments the biomaterialsmarket based on region (Asia Pacific, Europe, North America, and RoW), by type (Metallic Biomaterials [Stainless Steel, Titanium & Titanium Alloys, Cobalt-Chrome Alloys, Gold, Silver, Magnesium])(Ceramic Biomaterials [Calcium Phosphate, Zirconia, Aluminium Oxide, Calcium Sulphate, Carbon, Glass])(Polymeric Biomaterials [Polymethylmethacrylate (PMMA), Polyethylene, Polyester, Polyvinlychloride (PVC), Silicone Rubber, Nylon, PEEK, Other Polymers]). (Natural Biomaterials [Hyaluronic Acid, Collagen, Gelatin, Fibrin, Cellulose, Chitin, Alginates, Silk]).By application (Cardiovascular [Stents, Pacemakers, Implantable Cardiac Defibrillators, Heart Valves, Catheters, Vascular, Grafts, Guidewires, Sensors, Others]), (Orthopedic [Joint Replacement {Knee Replacement, Hip Replacement, Shoulder Replacements, Others}]), (Viscosupplementation), (Bioresorbabale Tissue Fixation Products [Suture Anchors, Interference Screws, Meniscal Repair Tacks, Meshes]), (Spine [Spinal Fusion], [Motion Preservation/Dynamic Stabilization {Pedicle-based rod Systems, Interspinous Spacers, Artificial Discs}], [Minimally Invasive Fusion Surgery], [Synthetic bone grafts], [Fracture fixation devices {Bone Plates, Screws, Pins, Rods, Wires}], (Ophthalmology [Intraocular Lens, Contact Lens, Functional Replacements of Ocular Tissues, Synthetic Corneas, Others]), (Dental [Dental Implants, Dental Bone Grafts & Substitutes, Dental Membranes, Tissue Regeneration Materials]), (Plastic Surgery [Soft Tissue Fillers, Craniofacial Surgery]), (Wound Healing [Wound Closure Devices {Sutures, Staples}], [Surgical Hemostats], [Internal Tissue Sealant], [Adhesion Barriers], [Hernia Meshes]), Tissue Engineering [Scaffolds For Regenerative Medicine, Nanomaterials For Biosensing Applications, Tailoring of Inorganic Nanoparticles], Neurology [Shunting Systems, Cortical Neural Prosthetics (CNP), Hydrogel Scaffolds for CNS Repair, Neural Stem Cell Encapsulation], (Other Applications [Drug Delivery Systems, Gastrointestinal Applications, Bariatric Surgery, Urinary Applications]). The report also provides a comprehensive review of market drivers, restraints, opportunities, challenges and trends in the biomaterials market.Key Benefits of Buying the Report:The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments.This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies.The report also helps stakeholders understand the pulse of the biomaterials market and provides them information on key market drivers, restraints, challenges, opportunities and trends.Read the full report: https://www.reportlinker.com/p04604339/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Ringover, opérateur téléphonique européen et éditeur d’une solution de collaboration cloud qui permet de gérer et piloter simplement ses communications professionnelles,annonce un premier tour de table de 10 millions d'euros pour lancer sa nouvelle stratégie de croissance et simplifier l'avenir des communications en entreprise. Expedition Capital a piloté cette opération de financement qui permettra à Ringover d'étendre sa portée en Europe et aux Etats-Unis. L'éditeur de logiciels SaaS a été créé à Paris en 2005 dans le but de développer des solutions de communication simples et intuitives pour les professionnels. Aujourd’hui Ringover transforme le système de téléphonie d'entreprise en une application facile à utiliser, accessible de n'importe où et à tout moment, et configurable en quelques clics, sans aucune compétence technique. Ringover combine de manière transparente les appels illimités, les outils de centre d'appels, la messagerie partagée et la visioconférence dans une seule application facile à utiliser pour les PME européennes. Ringover a connu une croissance soutenue depuis 2018, avec des revenus augmentant de plus de 800% et plus de 10 000 entreprises qui utilisent son logiciel. Cette levée de fonds permettra à l'entreprise de lancer son expansion internationale. Ringover souhaite notamment faire évoluer son offre et étendre ses opérations en Europe, avec l’ouverture de bureaux en Espagne et au Royaume-Uni, et aux États-Unis. Pour ce faire, l’entreprise va continuer de structurer ses équipes et a prévu de recruter une centaine de collaborateurs sur les prochains mois. Renaud Charvet, PDG et cofondateur de Ringover, a déclaré : « La mission de Ringover est de devenir un acteur majeur de la communication d’entreprise en fournissant sa solution de communication tout-en-un aux PME du monde entier. L'année écoulée a démontré le besoin de solutions évolutives, accessibles à tout moment et en tout lieu et qui sont intégrées aux outils métier pour augmenter la productivité. Nous sommes impatients de travailler avec Expedition Capital pour apporter la technologie de Ringover à davantage de PME afin de les aider à gérer efficacement leurs communications.

Exit: Sale of portfolio company FFX to H2 Equity Partners delivers 4.3x return The Board of Foresight 4 VCT Plc (“F4VCT” or “the Company”) is pleased to announce the successful sale of portfolio company FFX Group Limited (“FFX”), one of the UK's largest independent suppliers of high quality power tools, fixings and building supplies, to H2 Equity Partners (“H2”) on 22 January 2021. The transaction generated proceeds of £5.7 million at completion and the Company will receive up to £0.2 million of deferred consideration after 18 months subject to certain conditions, implying a cash on cash return of 4.3x the initial investment of £1.4 million made in October 2015, equivalent to an IRR of c.32%. The Company’s NAV per ordinary stood stands at 57.6p as at September 2020, to which the exit will add 0.4p, giving a pro forma NAV per ordinary share of 58.0p. Since F4VCT made its original investment in October 2015, the manager, Foresight Group LLP (“Foresight”) has taken a proactive approach to supporting the senior management team, introducing Chairperson George Adams who has extensive experience in the sector, including sixteen years at Kingfisher, three of which as Chair of Screwfix. The team was further strengthened with experienced, multi-channel retail executive CEO Chris Yates joining the business in 2019 and a Group Finance Director and eCommerce Director joining in 2020. During the five year investment period, FFX opened a new 60,000 ft2 distribution centre and a new head office in Kent, while staff numbers increased by more than 125. The business updated its brand and launched an extensive range of its own products. A direct sales team was established in order to expand FFX’s customer base to include larger contractors and specialist subcontractors and sell direct to site. Throughout, FFX has continued to develop its online presence both at ffx.co.uk and via eBay. Raymond Abbott, Chairman of Foresight 4 VCT said: “FFX has been a great success story for the Company and for our shareholders. We are delighted that Foresight has been able to make such a positive contribution to the growth of the business which has created over 125 new jobs, and we wish FFX every success for the future with H2.” ENDS For more information contact: Gary Fraser, Foresight Group: 0203 667 8181

Exit: Sale of portfolio company FFX to H2 Equity Partners delivers 4.3x return The Board of Foresight VCT Plc (“FVCT” or “the Company”) is pleased to announce the successful sale of portfolio company FFX Group Limited (“FFX”), one of the UK's largest independent suppliers of high quality power tools, fixings and building supplies, to H2 Equity Partners (“H2”) on 22 January 2021. The transaction generated proceeds of £11.1 million at completion and the Company will receive up to £0.3 million of deferred consideration after 18 months subject to certain conditions, implying a cash on cash return of 4.3x the initial investment of £2.7m made in October 2015, equivalent to an IRR of c.32%. The Company’s NAV per ordinary share stood at 68.8p as at September 2020, to which the exit will add 0.7p, giving a pro forma NAV per ordinary share of 69.5p. Since FVCT made its original investment in October 2015, the manager, Foresight Group LLP (“Foresight”) has taken a proactive approach to supporting the senior management team, introducing Chairperson George Adams who has extensive experience in the sector, including sixteen years at Kingfisher, three of which as Chair of Screwfix. The team was further strengthened with experienced, multi-channel retail executive CEO Chris Yates joining the business in 2019 and a Group Finance Director and eCommerce Director joining in 2020. During the five year investment period, FFX opened a new 60,000 ft2 distribution centre and a new head office in Kent, while staff numbers increased by more than 125. The business updated its brand and launched an extensive range of its own products. A direct sales team was established in order to expand FFX’s customer base to include larger contractors and specialist subcontractors and sell direct to site. Throughout, FFX has continued to develop its online presence both at ffx.co.uk and via eBay. John Gregory, Chairman of Foresight VCT said: “FFX has been a great success story for the Company and for our shareholders. We are delighted that Foresight has been able to make such a positive contribution to the growth of the business which has created over 125 new jobs, and we wish FFX every success for the future with H2.” ENDS For more information contact: Gary Fraser, Foresight Group: 0203 667 8181

The increasing modernization of armed forces to increase command and conrol capabilities throughenhanced situational awareness is the key factor that is expected to fuel the growth of the battlefield management systems market.New York, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Battlefield Management Systems Market by Solution Platform, System, Component, Installation Type, End-User, Region - Global Forecast to 2025" - https://www.reportlinker.com/p04819003/?utm_source=GNW However, lack of expertise that restrain the adoption of battlefield management systems hurdle the growth of this market.The battlefield management systems market includes major players Lockheed Martin Corporation (US), Northrop Grumman Corporation (US), Thales Group (France), Collins Aerospace (US), Leonardo SPA (Italy), BAE Systems (UK), Atos SE (France), Saab AB (Sweden), Aselsan (Turkey), Elbit Systems (Israel) and L3Harris Technologies (US).These players have spread their business across various countries includes North America, Europe, Asia Pacific, Middle East and the Rest of the World.COVID-19 has impacted their businesses as well. Industry experts believe that COVID-19 could affect battlefield management systems by 5-10% globally in 2020.The hardware segment of the market is projected to grow at the highest CAGR from 2020 to 2025.Based on solution, the hardware segment is projected to grow at the highest CAGR during the forecast period. The growth of the hardware segment is driven by the increasing demand for various components in a battlefield management system, such as, communication devices and computing devices among others, to improve operational efficiency.Based on system, the computing system segment is projected to lead the battlefield management systems market across the forecast periodBased on system, the computing system segment is projected to lead during the forecast period. The demand for sophisticated computing system to support decision making process by several defense organizations is driving the computing system segment growth globally.The North American region is estimated to account for the largest share of the battlefield management systems market in 2020The battlefield management systems market in the North American region is expected to witness substantial growth during the forecast period, owing to the high adoption of modernization of armed forces across the region.The break-up of the profiles of primary participants in the battlefield management systems market is as follows:• By Company Type: Tier 1 - 30%; Tier 2 - 40%; and Tier 3 - 30%• By Designation: C Level Executives - 40%; Directors - 32%; and Others - 28%• By Region: North America - 40%; Europe - 15%; Asia Pacific - 40%, Rest of the World - 5%Major players in the battlefield management systems market are Lockheed Martin Corporation (US), Northrop Grumman Corporation (US), Thales Group (France), Collins Aerospace (US), Leonardo SPA (Italy), BAE Systems (UK), Atos SE (France), Saab AB (Sweden), Aselsan (Turkey), Elbit Systems (Israel) and L3Harris Technologies (US).Research CoverageThis market study covers the battlefield management systems market across various segments and subsegments.It aims at estimating the size and growth potential of this market across different segments based on end user, platform, component, system, and region.This study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments undertaken by them, and key market strategies adopted by them.Reasons to Buy this ReportThis report is expected to help market leaders/new entrants by providing them the closest approximations of the revenue numbers for the overall battlefield management systems market and its segments.This study is also expected to provide region-wise information about the applications wherein battlefield management system solutions are used.It also aims at helping the stakeholders understand the competitive landscape of the market, gain insights to improve the position of their businesses, and plan suitable go-to-market strategies. This report is also expected to help them understand the pulse of the market and provide them with information on key drivers, restraints, challenges, and opportunities influencing the growth of the battlefield management systems market.Read the full report: https://www.reportlinker.com/p04819003/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

Digbi Health, the first company with a clinically proven genetics and gut-microbiome based program to safely and sustainably treat and manage obesity and associated inflammatory gut, skin and cardiometabolic health issues, is now available to Blue Shield of California members, as a fully covered program, on the health plan's Wellvolution platform.

CALGARY, AB, Jan. 26, 2021 /CNW/ - Calfrac Well Services Ltd.

Biopharma stocks advanced yet again in the week ended Jan. 22, with the change of guard at the White House generating broader market strength. Eli Lilly And ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14) 10X ...

JPMorgan Chase & Co. CEO Jamie Dimon is to be among the keynote speakers at next week's J.P. Morgan Healthcare Conference. After end...